Prevail Therapeutics Inc.
CIK 0001714798
Revenue (TTM)
—
Q3 Nov 2020
Net Income (TTM)
−$79.56M
−231.1% YoY
Q3 Nov 2020
EPS Diluted (TTM)
—
Q3 Nov 2020
Gross Margin
—
Q3 Nov 2020
Operating Margin
—
Q3 Nov 2020
Net Margin
—
Q3 Nov 2020
Free Cash Flow (TTM)
−$57.89M
Q3 Nov 2020
Cash
$81.73M
Q3 Nov 2020
Total Debt
—
Q3 Nov 2020
Shares Outstanding
34.25M sh
Q3 Nov 2020
Revenue & Net Income
Cash Flow
Revenue Growth (YoY)
No data available for this metric.